All News

FDA3.jpg

Filgotinib Bows Out of the RA Race in the USA

d Jack Cush, MD

Gilead Sciences Inc announced yesterday that it has decided not to pursue the an rheumatoid arthritis (RA) indicatin for its once daily oral JAK inhibitor, filgotinib (also named Jyseleca).

Read Article
JAK Janus

Consensus Recommendations on JAK Inhibitor Use

d Jack Cush, MD

A steering committee and task force was convened to develop recommendations for the use of Janus kinase (JAK) inhibitors in the treatment of immune-mediated inflammatory diseases (IMID).

Read Article
lung%2Cbright.jpg

Lung Cancer Survival With Autoimmune Disease

d Jack Cush, MD

Lung cancer risk is often increased with inflammation and autoimmune disease; a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.

Read Article
COVID.virus_.corona.jpg (keep)

COVID Risks in Systemic Autoimmune Patients

d Jack Cush, MD

There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture. 

Read Article
Lung Cancer Survival With Autoimmune Disease--a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments. Learn more below. https://t.co/ItVhityI1B https://t.co/tyTKAtGY2O

Links:

Dr. John Cush RheumNow ( View Tweet)
Panelists Dr. Richard Conway, Dr. David Liew, Dr. Sarah Mackie and Dr. Len Calabrese discuss giant cell arteritis studies presented at #ACR20. https://t.co/yjIDgbQ2jr https://t.co/mDPoXhRUee

Links:

Dr. John Cush RheumNow ( View Tweet)
Patient Outcomes on Low-Dose Steroids: Dr. Eric Dein ( @ejdein1) reviews abstract #1998 presented at #ACR20. https://t.co/i7s00z321O https://t.co/zrF0SnLJaq

Links:

Dr. John Cush RheumNow ( View Tweet)
Amer. College OBGYN practice advisory states women who are Pregnant or lactating should be offered COVID-19 vaccines. These vaccines have not been tested in pregnant women & a pregnancy test is not required to receive the vaccine https://t.co/qdbu8mkKWj

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase III RHAPSODY trial: open label rilonacept in 86 pts with active recurrent pericarditis (& elevated CRP). Rapid resolution was noted and during the drug withdrawal phase there were significantly fewer recurrences on rilonacept compared with placebo. https://t.co/oEGbsdKe8f

Links:

Dr. John Cush RheumNow ( View Tweet)

Global Burden of Disease study published in Arthritis & Rheumatology, shows that in 2017 there were 1.3 billion cases of musculoskeletal disorders worldwide, leading to 121,300 deaths and 138.7 million disability adjusted life years https://t.co/2UDQ0yjTbQ

Links:

Dr. John Cush RheumNow ( View Tweet)

After meeting with the FDA, Gilead has decided to suspend its application for the use of Filgotinib in RA in the USA. Safety concerns and the 200 mg dose were factors. Gilead believes it needs approval of 100 & 200 mg dose to be competitive in US market https://t.co/aPFN7hH4zH

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID Risks in Systemic Autoimmune Patients--There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. Read more below. https://t.co/SbMWR3slc3 https://t.co/Tul2W0YtLv

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/wzNmOzH4VE https://t.co/ct3K3KhWmX

Links:

Dr. John Cush RheumNow ( View Tweet)
Lookback at #ACR20. Drs. Cush and Kavanaugh discuss AS/SpA reports from ACR 2020 with Dr. John Reveille and Dr. Olga Petryna. https://t.co/DWLhD84IrI https://t.co/f8hQXbcvUQ

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Updates Session: Dr. Kathryn Dao ( @KDAO2011) reviews the FDA updates session from #ACR20. https://t.co/ZmHU82AeQu https://t.co/RsCKh88JRq

Links:

Dr. John Cush RheumNow ( View Tweet)
Tune in to the RheumNow podcast. Find us on Apple or Android devices. https://t.co/DPZUT2mqdA https://t.co/sHBzIsbRQn

Links:

Dr. John Cush RheumNow ( View Tweet)
NHANES study shows Peripheral neuropathy (11.6-13.5% population) was common and was independently associated with significant increase in all cause mortality (31-49% increased) in the U.S. population, even in the absence of diabetes. https://t.co/cjreodUIpa

Links:

Dr. John Cush RheumNow ( View Tweet)

Red Flags and Detours -- New RA Guidelines: Dr. Jack Cush dons his bullet-proof vest before taking aim at the new ACR RA Guidelines at presented at #ACR20. https://t.co/ZhfCiP59Qu https://t.co/5sui7b6wZ5

Links:

Dr. John Cush RheumNow ( View Tweet)
Addressing Fatigue in Rheumatoid Arthritis: Dr Eric Dein ( @ejdein1) #acr20 https://t.co/iKdwJqNlPE https://t.co/2u9pEH0QVq

Links:

Dr. John Cush RheumNow ( View Tweet)
My Experience as a COVID19 Vaccine Trial Participant by Dr. Kathryn Dao ( @KDAO2011) https://t.co/ILfXLUL8IZ https://t.co/Zd8gsCwnQo

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×